AAI Backs Mylan's Appeal Of Doryx Product-Hopping Suit
The American Antitrust Institute sided with Mylan Pharmaceuticals Inc. on Friday, urging the Third Circuit to review a district court decision that tossed the generic-drug maker's allegations that Warner Chilcott PLC...To view the full article, register now.
Already a subscriber? Click here to view full article